New Investigational Medication for Pain after Shingles (Postherpetic Neuralgia/PHN)

This eight-month study is evaluating the efficacy of two doses of this new medication compared to placebo in lowering pain intensity in patients with PHN.

Major Inclusion/Exclusion Criteria:

  • Ages 18-80
  • Persistent PHN pain for a minimum of 9 months following a the onset of a herpes zoster skin rash (shingles)
  • Must be on only one chronic pain drug, and must be willing to stay on that drug maintaining that stable dose for the duration of the study
  • Must not have any other neuropathic pain